| Roy A. Kellerman, Md, Llc | |
|
701 Cottage Grove Rd Ste A110 Bloomfield CT 06002-3082 | |
| (860) 243-5569 | |
| (860) 243-2622 |
| Full Name | Roy A. Kellerman, Md, Llc |
|---|---|
| Speciality | Internal Medicine |
| Location | 701 Cottage Grove Rd Ste A110, Bloomfield, Connecticut |
| Authorized Official Name and Position | Roy A Kellerman (DOCTOR) |
| Authorized Official Contact | 8602435569 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Roy A. Kellerman, Md, Llc 701 Cottage Grove Rd Ste A110 Bloomfield CT 06002-3082 Ph: (860) 243-5569 | Roy A. Kellerman, Md, Llc 701 Cottage Grove Rd Ste A110 Bloomfield CT 06002-3082 Ph: (860) 243-5569 |
| NPI Number | 1336314475 |
|---|---|
| Provider Enumeration Date | 04/29/2008 |
| Last Update Date | 08/02/2010 |
| Medicare PECOS PAC ID | 1658366349 |
|---|---|
| Medicare Enrollment ID | O20040420001212 |
News Archive
Antares Pharma, today announced the filing of a New Drug Application with the U.S. Food and Drug Administration for Anturol Gel in patients with overactive bladder.
In an analysis of pregnancies in Australia from 1999 to 2014 in which women were taking anti-epileptic drugs, fetal malformation rates fell over time in pregnancies where only one drug was taken, but rates increased in pregnancies where multiple drugs were taken.
HIV incidence among African-American men is nearly eight times that of white men, and twice that of Latino men. Incarceration, which disproportionately affects African-American men, is thought to be a factor in this wide disparity.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that it has completed enrollment and randomized the last patient in the global Phase 2/3 study with opaganib (Yeliva, ABC294640) in patients hospitalized with severe COVID-19 pneumonia (NCT04467840).
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336314475 | NPI | - | NPPES |
| 010023862CT05 | Other | CT | BC/BS |
| 110008097 | Other | CT | MEDICARE |
| 001238625 | Medicaid | CT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 23862 (Connecticut) | Primary |
| Provider Name | Roy A Kellerman |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1083780605 PECOS PAC ID: 6800881590 Enrollment ID: I20120619000000 |
News Archive
Antares Pharma, today announced the filing of a New Drug Application with the U.S. Food and Drug Administration for Anturol Gel in patients with overactive bladder.
In an analysis of pregnancies in Australia from 1999 to 2014 in which women were taking anti-epileptic drugs, fetal malformation rates fell over time in pregnancies where only one drug was taken, but rates increased in pregnancies where multiple drugs were taken.
HIV incidence among African-American men is nearly eight times that of white men, and twice that of Latino men. Incarceration, which disproportionately affects African-American men, is thought to be a factor in this wide disparity.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that it has completed enrollment and randomized the last patient in the global Phase 2/3 study with opaganib (Yeliva, ABC294640) in patients hospitalized with severe COVID-19 pneumonia (NCT04467840).
› Verified 1 days ago
News Archive
Antares Pharma, today announced the filing of a New Drug Application with the U.S. Food and Drug Administration for Anturol Gel in patients with overactive bladder.
In an analysis of pregnancies in Australia from 1999 to 2014 in which women were taking anti-epileptic drugs, fetal malformation rates fell over time in pregnancies where only one drug was taken, but rates increased in pregnancies where multiple drugs were taken.
HIV incidence among African-American men is nearly eight times that of white men, and twice that of Latino men. Incarceration, which disproportionately affects African-American men, is thought to be a factor in this wide disparity.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that it has completed enrollment and randomized the last patient in the global Phase 2/3 study with opaganib (Yeliva, ABC294640) in patients hospitalized with severe COVID-19 pneumonia (NCT04467840).
› Verified 1 days ago
David J Domenichini Md, Pc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 701 Cottage Grove Rd Ste B220, Bloomfield, CT 06002 Phone: 860-561-1007 Fax: 860-561-1222 | |
Ellis Medical Center, Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 701 Cottage Grove Rd, Suite A110, Bloomfield, CT 06002 Phone: 860-243-1864 | |
Joel M. Miller M.d. Pc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 2 Northwestern Dr Ste 300, Bloomfield, CT 06002 Phone: 860-242-6633 Fax: 860-286-8411 | |
E Y Evans Md Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 701 Cottage Grove Rd, Building C Suite 130, Bloomfield, CT 06002 Phone: 860-243-3352 Fax: 860-243-3329 | |
Charter Oak Health Center, Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 693 Bloomfield Ave Ste 101, Bloomfield, CT 06002 Phone: 860-550-7500 Fax: 860-216-4164 | |
Urgent Care Center Of Bloomfield Pllc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 699 Cottage Grove Rd, Bloomfield, CT 06002 Phone: 860-242-0034 Fax: 860-242-3301 |